



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, C12N 15/63, 15/85, 15/86, G01N 33/53, A61K 48/00		A1	(11) International Publication Number: WO 97/17359 (43) International Publication Date: 15 May 1997 (15.05.97)
(21) International Application Number: PCT/US96/16581 (22) International Filing Date: 14 October 1996 (14.10.96)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/556,424 9 November 1995 (09.11.95) US		Published <i>With international search report.</i>	
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).			
(72) Inventors: WILLIAMS, Lewis, T.; 3 Miraflores Lane, Tiburon, CA 94929 (US). MORISHITA, Kaoru; 5-19-17-202 Narashino-Dai, Funabashi-shi, Chiba 274 (JP).			
(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).			

(54) Title: NOVEL PROMOTER FOR VEGF RECEPTOR

(57) Abstract

This invention provides nucleic acid sequences for a VEGF receptor promoter, particularly for the Flt-1 promoter, expression vectors and recombinant host cells containing this promoter. It also provides methods for screening for drugs that regulate the transcriptional activity of the VEGF receptor promoter. Methods for endothelial-specific gene expression and treatment of disease, particularly by inhibiting angiogenesis, using novel gene constructs containing the VEGF receptor promoter are also provided. Transgenic animals having heterologous genes linked to the VEGF receptor promoter are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL PROMOTER FOR VEGF RECEPTOR

This invention was made with Government support under Grant No. HL 43821, awarded by the National Institutes of Health. The Government has certain rights 5 in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a novel promoter for 10 tissue specific gene expression and uses thereof. More particularly, this invention relates to nucleic acid sequences containing a functional promoter for the VEGF receptor, Flt-1 (fms-like receptor tyrosine kinase) that correspond in structure and/or properties to the native 15 genomic form of this promoter, the use of such nucleic acid sequences in screening for drugs that affect the VEGF/Flt-1 regulatory pathway, the use of such nucleic acid sequences in endothelial specific gene expression and other therapeutic and diagnostic applications.

20

2. Background

The establishment of a vascular supply is a critical requirement for the cellular inflow of nutrients, outflow of waste products and gas exchange in 25 most tissues and organs. Two separate processes for such blood vessel development and differentiation have been identified. One process, termed "vasculogenesis" takes place in the embryo and consists of the in situ 30 differentiation of mesenchymal cells into hemoangioblasts which are the precursors of both endothelial cells and blood cells. The other process, termed "angiogenesis" is the formation of new blood vessels by sprouting from a preexisting endothelium. This process is required not only for the further development of the embryonic 35 vasculature, but also for a wide variety of post natal processes such as wound healing and tissue and organ regeneration. In addition, angiogenesis has been

identified as a critical requirement for solid tumor growth and uncontrolled blood cell proliferation is an important pathogenic component in a variety of other disorders such as rheumatoid arthritis, atherosclerosis, 5 diabetes mellitus, retinopathies, psoriasis and retrorenal fibroplasia (all of which are characterized by excessive angiogenesis). Therefore, there is much interest in identifying angiogenesis factors and their receptors, identifying their mechanisms of action with 10 the goals of agonizing or antagonizing their activity and using their activity as a prognostic predictor of disease state.

Recently, vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) has been 15 identified as a prime regulator of normal and pathological angiogenesis. VEGF is a secreted growth factor which has the following properties: (1) it is a remarkably specific mitogen for endothelial cells; (2) it is angiogenic *in vivo* and induces vascular permeability; 20 (3) expression of VEGF and its receptors correlates with vasculogenesis and angiogenesis during embryonic development; and (4) VEGF is expressed in tumor cells, whereas the VEGF receptor is expressed exclusively in adjacent small blood vessels. VEGF plays a crucial role 25 for the vascularization of a wide range of tumors including breast cancers, ovarian tumors, brain tumors, kidney and bladder carcinomas, adenocarcinomas and malignant gliomas. Tumors produce ample amounts of VEGF, which stimulates the proliferation and migration of 30 endothelial cells (ECs), thereby inducing tumor vascularization by a paracrine mechanism.

The angiogenic effect of VEGF is mediated by its binding to high affinity cell surface VEGF receptors. Recently, three such high affinity receptors, Flt-1 35 (fms-like tyrosine kinase), Flk-1(fetal liver kinase-1; mouse homologue of kinase insert domain-containing receptor (KDR)) and Flt-4, have been cloned and

identified. These receptors are members of the type III subclass of the family of tyrosine kinases. The type III subclass is characterized by proteins containing seven immunoglobulin-like domains, a single transmembrane 5 region, and a kinase insert sequence. Of these, Flt-1 and Flk-1 are highly expressed by the endothelial cells in tumor blood vessels. In particular, high levels of Flt-1 expression are detected during periods of endothelial cell differentiation and neovascularization 10 during wound healing and embryonic vascular development. Since endothelial cell differentiation drives tumor angiogenesis by promoting vascular permeability of the developing tumor blood vessels, inhibition of the production and activity of the VEGF/Flt-1 ligand/receptor 15 system is a significant target for antiangiogenic anticancer strategies using anti-sense techniques, specific antibodies and specific inhibitors of VEGF/Flt-1 interactions.

Similarly, Flt-1 has been shown to be essential 20 for the organization of the embryonic vasculature. Furthermore, Flt-1 is significantly up-regulated in a variety of disease states such as papillary dermal edemas, hemangioblastomas, cytokine-induced cell proliferation, CNS tumors and malignant gliomas. In 25 comparison, there was little or no receptor expression in normal brain vasculature. Northern blot and in situ hybridization analysis showed significant Flt-1 mRNA transcription in capillary hemangioblastoma cells compared to normal brain cells. Therefore, it is 30 believed that Flt-1 is induced during tumor progression and that the VEGF/Flt-1 signalling pathway plays a significant role in stimulating tumor angiogenesis, a requirement for solid tumor growth.

Though Flt-1 expression is greatly enhanced in 35 diseased tissue such as solid tumors, little is known about the regulation of its expression. In addition, although as described earlier, Flt-1 expression is

localized in endothelial cells, particularly in the vascular endothelium, little is known about its molecular regulation in the endothelium. Whereas the genomic DNA sequence of a related receptor tyrosine kinase containing 5 two immunoglobulin-like domains, Tie, and its promoter region has been reported, the sequence of the promoter region of Flt-1 and other receptor tyrosine kinases of the type III subclass are not known. Knowing the promoter region of Flt-1 and other promoters of the type 10 III subclass would enable the regulation of Flt-1 and the other type III subclass receptor tyrosine kinases. Regulation of Flt-1 expression would provide methods of inhibiting diseases associated with excessive angiogenesis of the vascular endothelium and promoting 15 the processes of organ regeneration such as wound healing and the like. More generally, endothelial cells and the promoter elements controlling endothelial-specific gene expression are useful in the study of and therapy for diseases involving the vascular system, e.g., hemostasis, 20 wound healing, atherosclerosis, hypertension, diabetic retinopathy, rheumatoid arthritis, blood cell trafficking, inflammatory conditions and tumor angiogenesis. Endothelial cells are in direct contact with blood and are therefore optimally situated for 25 production of and secretion of desired proteins into the bloodstream or to neighboring cells. Expression systems where a gene is attached to an appropriate regulatory element targeted specifically to endothelial cells would allow for specific delivery of therapeutic agents to the 30 endothelium. The novel promoters, nucleic acid sequences and screening assays provided by this invention fulfill these and other needs.

3. Summary of Related Art

35 **Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor; B. Terman, M Dougher-Vermazen, M. Carrion, D. Dimitrov, D.**

Armellino, D Gospodarowicz, and P. Böhlen; Biochemical and Biophysical research Communications, V.187, No.3, 1579-1586, (1992); discloses cDNA and predicted amino acid sequence for KDR.

5 Nucleotide sequence and expression of a Novel Human Receptor-type Tyrosine kinase gene (*flt*) closely related to the *fms* family; M. Shibuya et al., Oncogene, 5, 519-524 (1990); discloses cDNA sequence of human Flt-1 gene.

10 The *fms*-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor; C. de Vries, J. Escobedo, H. Ueno, K. Houck, N. Ferrara, L. Williams; Science, 255, 989-991, (1992); describes cloning of human Flt-1.

15 Chromosomal Localization of *FLT4*, a Novel Receptor-Type Tyrosine Kinase Gene; F. Galland et al., Genomics, 13, 475-478, (1992); discloses the isolation, partial cDNA sequence and chromosomal localization of human Flt-4 and its deduced amino acid sequence.

20 Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth; K. Peters, C. De Vries, L. Williams; Proc. Natl. Acad. Sci. USA, 90, 8915-8919, (1993); discloses 25 that Flt-1 expression was localized in the endothelium.

FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin-like Loops and Is Expressed in Multiple Human Tissues and Cell Lines; K. Pajusola, O. Aprelikova, J. Korhonen, A. Kaipainen, L. Pertovaara, R. Alitalo, K. 30 Alitalo; Cancer Research, 52, 5738-5743, (1992); discloses cDNA sequence for Flt-4.

 Endothelial-Specific Gene Expression Directed by the *tie* Gene Promoter In Vivo; J. Korhonen et al., Blood, V.86, No.5, 1828-1835, (1995); discloses the human 35 and mouse *Tie* gene promoter sequences.

 Vascular Endothelial Cell lineage-specific Promoter in Transgenic Mice; Thorsten M. Schlaeger et

al., Development, 121, 1089-1098 (1995); studied function of Tie-2 gene promoter in transgenic mice and embryonic stem cells.

Inhibitor of Vascular Endothelial Cell Growth

5 **Factor**; R. Kendall, K. Thomas; PCT WO 94/21679, published 29 September 1994; discloses soluble mutants of Flt-1 which bind VEGF with high affinity but do not result in signal transduction.

FLK-1 is a Receptor for Vascular Endothelial

10 **Growth Factor**; PCT WO 94/11499, published 26 May 1994; discloses cloning of mouse Flk-1, uses of expressed Flk-1 to screen for drugs and inhibition of tumor growth using mouse cells encoding a transdominant-negative truncated Flk-1 mutant receptor.

15 **Identification of a Novel Human Receptor Tyrosine Kinase Gene**; PCT WO 92/14748, published 3 September 1992; discloses the cDNA sequence of human KDR.

SUMMARY OF THE INVENTION

20 This invention relates to a substantially purified nucleic acid molecule comprising a VEGF receptor promoter region, such as the promoters of the high affinity receptor tyrosine kinase subclass type III family and in particular the Flt-1 promoter.

25 This invention also relates to a nucleic acid molecule having a sequence selected from the group consisting of:

30 (a) a nucleic acid sequence substantially homologous to that of Figure 2 (SEQ ID NO:1), or a fragment thereof, exhibiting promoter activity;

(b) a nucleic acid sequence substantially complementary to the nucleic acid sequence of (a) or a fragment thereof;

35 (c) a nucleic acid sequence that hybridizes to the nucleic acid sequences of (a) or (b) or fragments thereof; and

(d) a nucleic acid identical to any of the sequences of (a), (b) or (c), with the proviso that any T may have been replaced by U.

The invention also relates to expression vectors comprising the aforementioned nucleic acid sequences and host cells transformed with these expression vectors.

The invention also relates to methods for detecting test agents which modulate transcription of the VEGF receptor promoters described above comprising contacting a host cell transformed with an expression vector comprising the VEGF receptor promoter DNA sequence operably linked to a reporter gene with the test agent and comparing the level of transcription produced by the test agent to the level of transcription produced in its absence.

One aspect of the invention provides methods of screening for test compounds that regulate the activity of the VEGF receptor promoter by:

(a) contacting a host cell in which the VEGF receptor promoter disclosed herein is operably linked to a reporter gene with a test medium containing the test compound under conditions which allow for expression of the reporter gene;

(b) measuring the expression of the reporter gene in the presence of the test medium;

(c) contacting the host with a control medium which does not contain the test compound but is otherwise identical to the test medium in (a), under conditions identical to those used in (a);

(d) measuring the expression of reporter gene in the presence of the control medium; and

(e) relating the difference in expression between (b) and (d) to the ability of the test compound to regulate the activity of the VEGF receptor promoter.

Another aspect of this invention provides methods of measuring the ability of a test compound to modulate VEGF receptor transcription by:

- (a) contacting a host cell in which the VEGF receptor promoter disclosed herein is operably linked to a reporter gene with an inducer of VEGF receptor promoter activity under conditions which allow for expression of the reporter gene;
- (b) measuring the expression of the reporter gene in the absence of the test compound;
- (c) exposing the host cells to the test compound either prior to, simultaneous with, or after contacting, the host cells with the inducer;
- (d) measuring the expression of the reporter gene in the presence of the test compound; and
- (e) relating the difference in expression between (b) and (d) to the ability of the test compound to modulate the transcription of the VEGF receptor.

The invention also relates to methods of modulating angiogenesis or thrombogenesis in a mammal comprising introducing into endothelial cells a vector comprising the nucleic acid sequence encoding a VEGF receptor promoter operably linked to a nucleic acid sequence encoding a protein, polypeptide, hormone, ribozyme or antisense RNA, which decrease vascular permeability and/or have antimitogenic activity or inhibit thrombogenesis and expressing the nucleic acid sequence.

The invention also relates to transgenic or chimeric animals whose cells express a heterologous gene under the transcriptional control of a VEGF receptor promoter, particularly the Flt-1 promoter.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 - Structure and restriction map of the Flt-1 genomic clones containing a 5' flanking region, exon 1, and a 5' portion of intron 1. Three clones 5 contained overlapping genomic segments. Solid boxes indicate the position of exon 1. The 3-kb EcoRI/XhoI fragments from all three clones were subcloned into pBluescript and restriction sites were determined. Restriction patterns of the three fragments were 10 identical. The nucleotide sequence of the 5' flanking region of Flt-1 between positions -1195 (BstXI) and +550 (XhoI) indicated by dotted line was determined by the Sanger method. Restriction sites for enzymes are indicated as follows: ApaI, Ap; AatII, At; B, BamHI; Bs, 15 BstXI; E, EcoRI; N, NaeI; Nc, NcoI; P, PstI; S, SmaI; Sp, SpeI; X, XhoI.

Fig. 2 - Nucleotide sequence (SEQ ID NO:1) of the 5' flanking region, exon 1, and a 5' portion of intron 1 of the Flt-1 gene. Position -1195 of Figure 2 20 corresponds to residue 1 of SEQ ID NO:1 and position +550 of Figure 2 corresponds to residue 1745 of SEQ ID NO:1. The numbering system used in the text is that shown in Figure 2. The transcription initiation site identified by primer extension and S1 mapping is indicated by an 25 asterisk and designated as +1 (Fig. 3). The consensus sequence of a TATA box, the putative binding sites for CREB/ATF (cAMP response element binding protein/activating transcription factor) and Ets (E26 transformation specific sequence), and the putative 30 transcription arrest site are underlined. A unique separated palindromic sequence is boxed. The nucleotide sequence of the synthetic oligonucleotide Oligo-F used for primer extension is also underlined. The 5' end of intron 1 is indicated by an arrow.

35 Fig. 3 - Identification of the transcription initiation site of Flt-1 by primer extension analysis. Total RNAs from BAEC, yeast tRNA, or lung tissue RNA were

analyzed using the synthetic oligonucleotide Oligo-F as a primer. Sequence reactions of the *Flt-1* genomic DNA using the same primer were run in parallel. An asterisk indicates the transcription initiation site.

5 Fig. 4 - Expression of luciferase fusion gene constructs containing 5' deleted *Flt-1* promoter sequences. The constructs were transiently transfected into BAEC (solid), NIH-3T3 cells (open), and HFF (shaded). Luciferase activities were normalized to 10 internal pSV-CAT control in each extract to adjust for differences in transfection efficiencies. The luciferase activity obtained with transfection of pSV-luc is arbitrarily set at 1 for each cell type. All other luciferase activities are given relative to this value. 15 Each value is the mean of at least three independent experiments.

Fig. 5. - Expression of the *Flt-1* promoter (-748/+284)-luciferase fusion gene in various human primary cells and established cell lines. The 20 replication-deficient recombinant adenovirus AdexFLTP-luc carrying the *Flt-1* promoter (-748/+284)-luciferase-fusion gene and AdexCA1LacZ were co-infected into various human primary endothelial cells (HAEC, HPEC, HUVEC) bovine adrenal endothelial cells (BAE), human primary mammary 25 epithelial cells (HMEC), human primary aortic smooth muscle cells (AOSMC), NCI-H292 cells, human foreskin fibroblasts (HFF), rat primary aortic smooth muscle cells (rat SMC), and NIH-3T3 cells. Luciferase activities were normalized to β -galactosidase activities in each extract. 30 Each value is the mean of at least three independent experiments.

Fig. 6. - Effect on *Flt-1* promoter activity by: (A) further deletion of a 5' flanking region and (B) internal deletion of CREB/ATF element. (A) Constructs 35 containing shorter promoter regions than the constructs shown in Fig. 4 and 5 were analyzed. (B) Four internal bases of the CREB/ATF element (ACGT out of TGACGTCA) were

deleted in Δ CRE(-962/+284)-luc. These constructs were transiently transfected into BAEC. The data are presented in the same manner as in Fig. 4. Each value is the mean of two independent experiments. Filled 5 triangles indicate the CREB/ATF element.

Fig. 7. - Negative effect of intron 1 on the Flt-1 promoter activity. Both (-2.5k/+550)sp-luc and (-2.5k/+4.5k)sp-luc contain a hybrid intron consisting of 220 bp or 2.3 kb of the 5' portion of the first intron of 10 Flt-1 and a 3' splice site of a mouse immunoglobulin gene. By contrast, (-2.5k/+550)-luc contains only 220 bp of the 5' portion of the first intron of Flt-1. (+550/-2.5k)-luc has the promoter oriented in the reverse direction. These constructs were transiently transfected 15 into BAEC. The data are presented in the same manner as in Fig. 4. Each value is the mean of two independent experiments. The shaded box indicates a 3' splice site of a mouse immunoglobulin gene.

Fig. 8. - Comparison between the sequence 20 surrounding the transcription arrest site in the first intron (SEQ ID NO: 2) of the adenosine deaminase gene and the homologous region in the first intron of flt-1 (residues 1603 to 1627 of SEQ ID NO: 1). Asterisks indicate identical bases. The core sequence of the 25 transcription arrest site is boxed. The underlined bases have been shown to be important for full transcription arrest activity by point mutational analysis.

DETAILED DESCRIPTION OF THE INVENTION

30 This invention relates to novel promoters for the VEGF receptor, nucleic acid constructs comprising such promoters operatively linked to genes encoding a gene product, such as a protein, polypeptide, hormone, ribozyme, or antisense RNA, recombinant cells comprising 35 such nucleic acid constructs, screening for therapeutic drugs using such cells and endothelial tissue-specific gene expression using these novel promoter sequences.

Before describing the invention in greater detail the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

5 The term "receptor tyrosine kinase subclass type III" refers to the subfamily of receptor tyrosine kinases characterized by a high affinity binding site for VEGF (vascular endothelial growth factor) and containing seven immunoglobulin-like domains, a single transmembrane
10 region, and a kinase insert sequence. These receptors are exemplified by Flt-1, Flt-4 and Flk-1/KDR.

The term "nucleic acid molecule" is meant to include DNA, RNA and mixed DNA-RNA sequences. In addition to the typically found A, T, U, G and C
15 residues, a nucleic acid molecule may also include related residues such as, for example, inosine (I).

The term "promoter region" refers to a DNA sequence that functions to control the transcription of one or more genes, located upstream with respect to the
20 direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited
25 to transcription factor binding sites, repressor and activator protein binding sites, calcium or cAMP responsive sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from
30 the promoter.

The term "promoter activity" refers to the extent of transcription of a gene that is operably linked to the promoter whose promoter activity is being measured. The promoter activity may be measured directly
35 by measuring the amount of RNA transcript produced, for example by Northern blot or indirectly by measuring the

product coded for by the RNA transcript, such as when a reporter gene is linked to the promoter.

The term "substantially purified" refers to a nucleic acid sequence, polypeptide, protein or other compound which is essentially free, i.e. is more than about 50% free of, preferably more than about 70% free of, more preferably more than about 90% free of, the polynucleotides, proteins, polypeptides and other molecules that the nucleic acid, polypeptide, protein or other compound is naturally associated with.

The term "operably linked" refers to linkage of a DNA segment to another DNA segment in such a way as to allow the segments to function in their intended manners.

A DNA sequence encoding a gene product is operably linked to a regulatory sequence when it is ligated to the regulatory sequence, such as, for example, promoters, enhancers and silencers, in a manner which allows modulation of transcription of the DNA sequence, indirectly or indirectly. For example, a DNA sequence is operably linked to a promoter when it is ligated to the promoter downstream with respect to the transcription initiation site of the promoter, in the correct reading frame with respect to the transcription initiation site and allows transcription elongation to proceed through the DNA sequence. An enhancer or silencer is operably linked to a DNA sequence coding for a gene product when it is ligated to the DNA sequence in such a manner as to increase or decrease respectively the transcription of the DNA sequence. Enhancers and silencers may be located upstream, downstream or embedded within the coding regions of the DNA sequence. A DNA for a signal sequence is operably linked to DNA coding for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide. Linkage of DNA sequences to regulatory sequences is typically accomplished by ligation at suitable restriction sites or adapters or

linkers inserted in lieu thereof using restriction endonucleases known to one of skill in the art.

The term "transcriptional regulator" refers to a biochemical element that acts to prevent or inhibit the 5 transcription of a promoter-driven DNA sequence under certain environmental conditions (e.g., a repressor or nuclear inhibitory protein), or to permit or stimulate the transcription of the promoter-driven DNA sequence under certain environmental conditions (e.g., an inducer 10 or an enhancer).

The term "induction" refers to an increase in gene transcription or expression brought about by a transcriptional inducer, relative to some basal level of transcription.

15 The term "repression" refers to a decrease in gene transcription or expression brought about by a transcriptional repressor, relative to some basal level of transcription.

The term "heterologous DNA" or "heterologous 20 RNA" refers to DNA or RNA that does not occur naturally as part of the genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differs from that which it is in found in nature. 25 Heterologous DNA and RNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such DNA encodes RNA and proteins that are not normally produced by the cell 30 in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is present. Heterologous DNA or RNA may also referred to as foreign DNA or RNA. Any DNA or RNA that one of skill in the art 35 would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous DNA or heterologous RNA. Examples of

heterologous DNA include, but are not limited to, DNA that encodes proteins, polypeptides, receptors, reporter genes, transcriptional and translational regulatory sequences, selectable or traceable marker proteins, such 5 as a protein that confers drug resistance, RNA including mRNA and antisense RNA and ribozymes.

A "reporter gene" is a DNA molecule that expresses a detectable gene product, which may be RNA or protein. The detection may be accomplished by any method 10 known to one of skill in the art. For example, detection of mRNA expression may be accomplished by using Northern blots and detection of protein may be accomplished by staining with antibodies specific to the protein. Preferred reporter genes are those that are readily 15 detectable. A reporter gene may be operably linked in a DNA construct with a regulatory DNA sequence such that detection of the reporter gene product provides a measure of the transcriptional activity of the regulatory sequence. Examples of reporter genes include, but are 20 not limited to, those coding for chloramphenicol acetyl transferase (CAT), luciferase, β -galactosidase and alkaline phosphatase.

The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either 25 ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double and single stranded DNA, triplex DNA, as well as double and single stranded RNA. It also includes modified, for example, by methylation 30 and/or by capping, and unmodified forms of the polynucleotide.

The term "recombinant polynucleotide" as used herein refers to a polynucleotide of genomic, cDNA, semisynthetic or synthetic origin which, by virtue of its 35 origin or manipulation: (1) is not associated with all or a portion of the polynucleotide with which it is associated in nature and/or (2) is linked to a

polynucleotide other than that to which it is linked in nature.

The term "cDNA" or *complementary DNA* refers to single stranded or double stranded DNA sequences obtained 5 by reverse transcription of messenger RNA isolated from a donor cell. For example, treatment of messenger RNA with a reverse transcriptase such as AMV reverse transcriptase or M-MuLV reverse transcriptase in the presence of an oligonucleotide primer will furnish an 10 RNA-DNA duplex which can be treated with RNase H, DNA polymerase and DNA ligase to generate double stranded cDNA. If desired, the double stranded cDNA can be denatured by conventional techniques such as shearing to generate single stranded cDNA.

15 An "expression vector" is any genetic element, e.g., a plasmid, a chromosome, a virus, behaving either as an autonomous unit of polynucleotide replication within a cell (i.e. capable of replication under its own control) or being rendered capable of replication by 20 insertion into a host cell chromosome, having attached to it another polynucleotide segment, so as to bring about the replication and/or expression of the attached segment. Suitable vectors include, but are not limited to, plasmids, bacteriophages and cosmids. Vectors may 25 contain polynucleotide sequences which are necessary to effect ligation or insertion of the vector into a desired host cell and to effect the expression of the attached segment. Such sequences differ depending on the host organism; they include promoter sequences, such as the 30 novel Flt-1 promoters of the present invention, to effect transcription, enhancer sequences to increase transcription, ribosomal binding site sequences and transcription and translation termination sequences. Alternatively, expression vectors may be capable of 35 directly expressing gene products encoded therein without ligation or integration of the vector into host cell DNA sequences.

The terms "transformed" or "transfected" are used interchangeably and refer to the process by which exogenous DNA or RNA is transferred or introduced into an appropriate host cell. Typically, the exogenous DNA will 5 comprise the promoter regions of this invention, preferably the Flt-1 promoter, operably linked to a heterologous DNA sequence. Such transfected cells include stably transfected cells wherein the inserted DNA is rendered capable of replication in the host cell. 10 Typically, stable transfection requires that the exogenous DNA be transferred along with a selectable marker gene, such as for example, a gene that confers antibiotic resistance, which enables the selection of the stable transfectants. This marker gene may be ligated to 15 the exogenous DNA or be provided independently by simultaneous cotransfection along with the exogenous DNA. Transfected cells also include transiently expressing cells that are capable of expressing the RNA or DNA for limited periods of time. The host cell may be a 20 prokaryotic or eukaryotic cell. The transfection procedure depends on the host cell being transfected. It can include packaging the polynucleotide in a virus as well as direct uptake of the polynucleotide. Transformation can result in incorporation of the 25 inserted DNA into the genome of the host cell or the maintenance of the inserted DNA within the host cell in plasmid form. Methods of transformation/transfection are well known in the art and include, but are not limited to, direct injection, such as microinjection, viral 30 infection, particularly replication-deficient adenovirus infection, electroporation, lipofection, calcium phosphate-mediated direct uptake and the like.

The term "transfer vector" refers to a plasmid that enables the integration of a recombinant gene into 35 virus DNA by homologous recombination.

The term "host cell" generally refers to prokaryotic or eukaryotic organisms and includes any

transformable organism which is capable of expressing a protein and can be, or has been, used as a recipient for expression vectors or other transfer DNA. Cells of the vascular endothelium are preferred host cells for 5 expression vectors comprising the VEGF receptor promoters of this invention.

The term "recombinant cells" refers to cells that have been modified by the introduction of heterologous DNA or RNA. Endothelial cells, particularly 10 cells of the vascular endothelium are preferred for introduction of heterologous DNA operably linked to the VEGF receptor promoters of this invention.

It is to be understood that this invention is intended to include other forms of expression vectors, 15 host cells and transformation techniques which serve equivalent functions and which become known to the art hereto.

As noted above, the present invention relates to a recombinant nucleic acid molecule comprising the 20 promoter region of a VEGF receptor. This invention provides a promoter region for tyrosine kinase VEGF receptors, subclass type III, such as Flt-1, Flk-1/KDR and Flt-4, in particular, Flt-1. This invention provides a nucleic acid molecule having a sequence selected from 25 the group consisting of:

(a) the nucleic acid sequence substantially homologous to that of SEQ ID NO: 1 or a fragment thereof, exhibiting promoter activity, in particular Flt-1 promoter activity;

30 (b) a nucleic acid sequence substantially complementary to said nucleic acid sequence of (a), or a fragment thereof; and

(c) a nucleic acid sequence that hybridizes to said nucleic acid sequences of (a) or (b) or fragments 35 thereof.

This invention also provides novel deletion constructs of the VEGF receptor promoter which either

increase or decrease promoter activity beyond that of the naturally occurring promoter. The deletion constructs are obtained by deleting from the VEGF receptor promoter sequence shown in Figure 2 (SEQ ID NO: 1) those segments 5 shown by Applicants to have negative or positive regulatory activity, such as the residues 839 to 862 (residues -356 to -333 of Figure 2), residues 1479 to 1745 (residues +284 to +550 of Figure 2), residues 447 to 612 (-748 to -583 of Figure 2) and residues 956 to 1120 10 (residues -239 to -75 of Figure 1) of SEQ ID NO: 1, or portions thereof. The numbering for residue positions used above and elsewhere in the specification refers to the numbering used in Figure 2 unless stated otherwise. Deletion constructs in which negative regulatory regions 15 have been removed result in enhanced promoter activity.

Such constructs provide greater sensitivity than the native promoter when used to screen for drugs which affect VEGF receptor promoter activity.

The nucleic acid molecules of this invention 20 are useful in effecting tissue specific expression in endothelial cells as described in greater detail below and screening for drugs that selectively modulate transcription in endothelial cells and drugs that modulate angiogenic processes.

25 Preferably, such nucleic acid molecules will be substantially homologous to the nucleic acid sequence shown in Figure 2 (SEQ ID NO:1), and more preferably to the sequence of residues 447 to 1479 of SEQ ID NO:1 (-748 to +284 of Figure 2). Substantial homology in the 30 nucleic acid context means that the segments, or their complementary strands, when compared, are the same when properly aligned, with the appropriate nucleotide insertions and deletions, in at least about 60% of the nucleotides, typically, at least about 70%, more 35 typically, at least about 80%, usually, at least about 90%, and more usually, at least, about 95-98% of the nucleotides. Alternatively, substantial homology exists

between two segments when the segments or their complementary strands will hybridize under stringent hybridization conditions to a template strand. Selective hybridization exists when the hybridization is more 5 selective than total lack of specificity. See, Kanehisa, Nucleic Acids Res., 12:203-213 (1984).

The nucleic acid sequences provided above can be used by those skilled in the art to practice the invention as disclosed herein without undue 10 experimentation using, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor Laboratory Press, New York, (1989) and F.M. Ausubel et al eds., Current Protocols in Molecular Biology, John Wiley and Sons (1994).

15 Alternatively, those skilled in the art can practice the invention by repeating the experimental procedures carried out by the inventors and described herein for the isolation and characterization of the VEGF receptor promoters, their transfection into host cells, 20 and vascular endothelial cell-specific expression of heterologous DNA operably linked to said VEGF receptor promoters.

Cloning and Characterization of the Flt-1 Promoter

25 *Restriction Map and Exon-intron Organization of 5'-specific Human Flt-1 Genomic Clones* - Genomic clones from a human placental genomic library were obtained by screening with a human Flt-1 cDNA 5'-end 600 bp *EcoRI/AccI* DNA fragment. Three overlapping but not 30 identical genomic clones were selected for further analysis based on the result of Southern analyses using the human Flt-1 cDNA 5'-end oligo DNA probe. The restriction maps of these clones were determined by the partial restriction method and are shown in Fig. 1. The 35 3 kb *EcoRI/XhoI* fragments from all three clones were subcloned into pBluescript-KS(+). Detailed restriction maps and partial sequences showed that these 3 kb

fragments were identical. Sequence Analysis of the Promoter Region of *Flt-1* - The nucleotide sequence of a 1.8 kb *Bst*XI/*Xho*I fragment from clone #4-18 (Fig. 1) was determined by the Sanger dideoxy termination method. 5 This sequence of this fragment is shown in Fig. 2 (SEQ ID NO:1) and contains exon 1, a 5' portion of intron 1, and the 5' flanking region of *Flt-1* containing putative transcription factor binding sites such as a TATA box, a CREB/ATF element, and an ETS binding site. The first 10 intron contains a putative transcription arrest site as discussed below.

Transcription Initiation Site - To identify the transcription initiation site of *Flt-1*, primer-extension analysis was performed with total RNA from HUVEC and 15 human lung tissue (Fig. 3). The transcription initiation site was mapped to an adenosine residue 25-bp down-stream from the TATA box. This result was confirmed by S1 mapping analysis.

This invention also provides fragments of the 20 genomic VEGF receptor promoter, which fragments may possess enhanced transcriptional activity relative to the genomic promoter. This invention also provides expression vectors comprising the VEGF receptor promoter, in particular the promoter region of the VEGF receptor, 25 *Flt-1*, operably linked to a heterologous gene encoding a gene product and host cells transformed or transfected with such expression vectors. The gene product may be a reporter gene, as will typically be the case when the host cells of the invention are being used to screen for 30 expression of the reporter gene in the presence of a putative regulator of the promotional activity of the *Flt-1* promoter. Alternatively, the gene product may be a protein, polypeptide, hormone, ribozyme, antisense messenger RNA and the like when endothelial-specific 35 tissue expression of the protein, polypeptide, hormone, ribozyme, antisense messenger RNA and the like is desired.

Fragments of the VEGF receptor promoter were obtained by constructing a series of 5'-deletion mutant plasmids fused to the luciferase reporter gene by partial exonuclease digestion. To determine the sequences 5 essential for efficient transcription of the Flt-1 promoter, a DNA construct was prepared by fusing a DNA segment extending from +284 bp to -2.5 kb of the sequence in Fig. 2 to a luciferase gene in the promoterless plasmid pMC-luc vector described in the Examples. This 10 construct, designated as p(-2.5k/+284)-luc, contains 2.5 kb of the promoter region, 230 bp of exon 1, and 54 bp of the 5' end of the first intron, and was used to generate a series of 5' end deletions (Fig. 4 and 6A). The resultant constructs are referred to as p(X/Y)-luc. For 15 each, X and Y represent the 5'- and 3'- end position respectively in the nucleotide sequence with reference to the numbering used in Figure 2. Several 5'-deletion mutants were produced: p(-962/+284)-luc, p(-748/+284)-luc, p(-583/+284)-luc, p(-386/+284)-luc, 20 p(-356/+284)-luc, (-333/+284)-luc, p(-239/+284)-luc, p(-219/+284)-luc, p(+151/+286)-luc and p(-75/+284)-luc. Each construct was transfected into bovine adrenal 25 endothelial cells (BAEC), murine fibroblast NIH-3T3 cells and human foreskin fibroblast cells (HFF) and promoter activity was assessed by measuring luciferase activity.

Promoter activity of these deletion mutants in BAEC, NIH-3T3 and HFF is shown in Figure 4. Deletion mutant p(-748/+248)-luc showed the highest activity. Transfection of the series of constructs deleted from 30 -2.5 kb to +151 showed the presence of at least two regions, 2500 to -1195 and -356 to -333, containing negative regulatory sequences, and two regions, -748 to -583 and -239 to -75, containing positive regulatory sequences. Deletion to +151 decreased luciferase 35 activity to the level of the promoterless plasmid pMC-luc.

Transfection of the p(-2.5k/+550)-luc construct, which contains 220 bp of the first intron of *flt-1* (containing the 5' splice site but not the 3' splice site), resulted in no luciferase activity (Fig. 5 7). There are several mechanisms by which introns have been shown to regulate gene expression: 1) transcriptional attenuation by a silencer, 2) formation of double-stranded RNA by antisense transcripts (Krystal, G., Armstrong, B. C., and Battey, J. F. (1990) *Mol. Cell. 10 Biol.* **10**, 4180-4191; Kimelman, D. and Kirschner, M. W. (1989) *Cell* **59**, 687-696), and 3) transcription arrest (Kash, S. F., Innis, J. W., Jackson, A. U., and Kellems, R. E. (1993) *Mol. Cell. Biol.* **13**, 2718-2729). In the case of *flt-1*, the first intron contains a sequence which 15 is very similar to the transcription arrest site in the first intron of adenosine deaminase (ADA) gene (Fig. 8). Thus, it appears that the negative regulation conferred by intron 1 may be due to transcriptional arrest.

In conclusion, it has been shown in a series of 20 transfection assays that a 1 kb DNA fragment of the 5'-flanking sequence of *Flt-1* has functional activity in vascular endothelial cells but limited activity in epithelial cells, vascular smooth muscle cells, and fibroblasts. It has also been shown that the *Flt-1* CREB/ATF element was essential for basal transcription 25 and the first intron of *Flt-1* negatively regulated gene expression.

Endothelial Cell specificity of the *Flt-1* Promoter

30 This invention also provides methods for tissue-specific expression of heterologous genes or DNA in endothelial cells, particularly in vascular endothelial cells, employing the *Flt-1* promoter. Convention drug delivery technology is not amenable to 35 tissue specific delivery of bioactive species. For example, direct delivery of cytokines such as IL-2, TNF α and gamma interferon has been hampered by their low half

life, poor bioavailability and high toxicity. This invention provides methods of directly delivering bioactive species to endothelial cells, particularly vascular endothelial cells, via their specific endogenous 5 production in the endothelium. The vectors provided by this invention are useful for the tissue specific expression of genes useful for treating diseases affecting the vascular endothelium such as, but not limited to, hypertension, thrombosis, atherosclerosis and 10 restenosis. Inflammatory diseases characterized by endothelial cell activation should also be susceptible to inhibition by genes delivered via the vectors of this invention.

The tissue specific regulatory sequences 15 present in human genomic DNA, as described herein, can also be used to target endothelial cells for killing. Thus, tumor cells or infected cells can be targeted for death, as has been done using antibodies specific for the tumor cell or the infected cell to deliver a toxic agent 20 to the diseased cell. As described above, the preferred regulatory-sequence for liver or kidney specific expression includes the promoter regions of the VEGF receptor of the present invention.

The regulatory sequences can be used to target 25 expression of a "toxic" peptide of bacterial, plant or animal origin (Frankel, A.E. et al., *Ann. Rev. Med.* 37:125-142 (1986)) to an endothelial cell, preferably in the vascular endothelium. Any of a number of toxic proteins of bacterial origin, such as *Pseudomonas* 30 exotoxin A or Diphtheria toxin (Endo, Y. et al., *J. Biol. Chem.* 262:5908-5912 (1987)) are known. Examples of well-known toxic proteins, primarily single chain ribosomal inhibitory proteins, of plant origin, include ricin or abrin A chain, Trichosanthin (Gu, Z. et al., *Acta Chemica Sinica* 43:943-945 (1984)) and the non-toxic anti-HIV 35 protein, TAP 29, derived therefrom (Lee-Huang, S. et al. *Proc. Natl. Acad. Sci. (USA)*, 88:6570-6574 (1991)), GLQ

223 isolated from *T. kirilowil* (McGrath, M.S. et al., Proc. Natl. Acad. Sci. (USA) 86:2844-2848 (1989)), momordica-derived inhibitors (Jimenez, A. et al., Annu. Rev. Microbiol. 39:649-672 (1985)) including MAP 30, an 5 anti-tumor and anti-viral protein recently isolated in the laboratory of the present inventor from *Momordica charantia* (Lee-Huang, S. et al., FEBS Lett. 272:12-18 (1990)), the pokeweed anti-viral proteins (PAP) (Irvin, J.D. et al., Arch. Biochem. Biophys. 200:418-425 (1980)), 10 dianthins (Stripe, F. et al., Biochem. J. 295:399-405 (1981)) and gelonin (Stripe, F. et al., L7. Biol. Chem. 255:6947-53 (1980)). Also intended are a new class of anti-HIV agents, GAP 31, DAP 32 and DAP 30 (Lee-Huang, S. et al. FMS Lett. 291:139-144 (1991) ; Lee-Huang, S. et 15 al., Biofactors 4:37-41 (1992)). An animal-derived toxic protein is tumor necrosis factor- α . Such toxic proteins may act as antiviral agents or an antitumor agents.

The regulatory sequences of the present invention may also be used to target an antisense 20 oligonucleotide (Hambor, J.E. et al., J. Exp. Med. 168:1237-1245 (1988) ; Holt, J.T. et al., Proc. Nat'l. Acad. Sci. 83:4794-4798 (1986); Izant, J.G. et al., Cell 36:1007-1015 (1984); Izant, J. G., et al., Science 229:345-352 (1985) and De Benedetti, A. et al., Proc. 25 Natl. Acad. Sci. 84:658-662 (1987)), for example, of a specific oncogene, to the liver or kidney and to kill the respective tumor cells. The antisense oligonucleotides may range from 6 to 50 nucleotides, and may be as large as 100 or 200 nucleotides. The oligonucleotides can be 30 DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotides can be modified at the base moiety, sugar moiety, or phosphate backbone.

Examples of using various tissue specific 35 regulatory sequences, as disclosed herein, for targeted expression and for killing of specific cells are known in the art, including expression of (1) SV40 large T antigen

in pancreatic β cells by insulin regulatory sequence (Hanahan, D., *Nature* 315:115-122 (1985)), (2) diphtheria toxin A chain in pancreas by elastase I regulatory sequence (Palmiter, R.D. et al., *Cell*, 50:435-443 (1987)), 5 and (3) ricin or diphtheria toxin A chain in lens cells by the tissue specific regulatory sequence of crystallin genes (Borrelli, E.R. et al., *Proc. Natl. Acad. Sci. (USA)* 85:7572-7576 (1988)).

When used in such tissue specific applications, 10 the expression vectors of this invention can be used to express heterologous genes in addition to luciferase or chloramphenicol transferase. Generally, in addition to the heterologous gene operably linked to the VEGF receptor promoter sequences of this invention, the vector 15 will contain at least one eukaryotic marker gene, the appropriate eukaryotic transcriptional and translational stop signals, at least one Shine-Delgarno sequence and initiator codon, a signal that signals polyadenylation of the transcribed mRNA, and any other DNA sequences 20 necessary or preferred for the appropriate transcription and translation of the heterologous DNA. These additional sequences may include a signal sequence for proteins to be exported or secreted from the host cell and at least one gene for a transcriptional regulator 25 protein. If the vector is used as an extrachromosomal replicating DNA in the eukaryotic cell where it is expressed, the vector will include an origin of replication that functions in the host cell. When the vector is to be integrated into the host chromosomal DNA, 30 it will contain elements necessary to facilitate its integration into the host genome. These elements may be provided by viral vectors such as vaccinia and adenovirus, or by nonviral recombinant plasmids.

DNA is commonly transferred or introduced into 35 recipient mammal cells by calcium phosphate-mediated gene transfer, electroporation, lipofection, viral infection and the like. General methods, vectors and general

considerations for gene transfer and expression may be found in M. Kriegler, Gene Transfer and Expression: A Laboratory Manual, Stockton Press (1990). Direct gene transfer to cells in vivo is achieved by the use of 5 modified viral vectors, including retroviruses, adenoviruses, adeno-associated viruses and herpes viruses, liposomes, and direct injection of DNA into certain cell types. In this manner, recombinant expression vectors and recombinant cells containing the 10 novel VEGF promoters of the present invention operably linked to desired heterologous gene can be delivered to specific target cells in vivo. See, e.g., Wilson, Nature, 365: 691-692 (1993); Plautz et al, Annals NY Acad. Sci., 716: 144-153 (1994); Farhood et al, Annals NY Acad. Sci., 716: 23-34 (1994) and Hyde et al Nature, 362: 15 250-255 (1993). Furthermore, cells may be transformed ex vivo selected as described earlier and introduced directly at localized sites by injection, e.g., intra-articular, intracutaneous, intramuscular and the like.

Another aspect of this invention also provides 20 methods of inhibiting angiogenesis of a tumor by transfecting endothelial cells lining the tumor with a vector comprising a nucleic acid sequence for a VEGF receptor promoter, preferably the Flt-1 promoter, 25 operably linked to a gene that codes for a species that inhibits vascular permeability or has antimitogenic activity. Expression of such species prevent vascularization of the tumor, block nutrient access to the tumor and thereby inhibit tumor growth. The encoded 30 species may be peptides, proteins, hormones, ribozymes, antisense RNA, and the like. Ex vivo transfection methods for delivering the species to the tumor may be used. Such methods generally involve explanting cells from the mammal, transfecting the cells with an 35 expression vector comprising a nucleic acid comprising a VEGF receptor promoter operatively linked to gene coding for the desired species and selecting and reimplanting

into the mammal cells which have incorporated and express said nucleic acid. In vivo transfection can be accomplished by methods such as direct injection of the above expression vectors.

5 Another aspect of the invention provides methods of inhibiting thrombogenesis in a mammal by transfection of vascular endothelial cells with an expression vector comprising the novel promoter sequences of this invention operably linked to a gene that encodes
10 for a protein that inhibits thrombogenesis by, for example, enhancing fibrinolysis or increasing the anticoagulability of blood. In general, thrombus formation occurs on the surface of vascular endothelial cells. Thus, endothelial cells are a good target for
15 expression of such proteins. The tissue-specific expression made possible by the VEGF receptor promoters disclosed herein, particularly the Flt-1 promoter, provides a method for preferentially expressing these proteins in vascular endothelial cells. Proteins whose
20 expression can be placed under the regulatory control of the promoter sequences for the purpose of inhibiting thrombogenesis include, but are not limited to:

(1) Tissue plasminogen activator (t-PA), urokinase (u-PA), single chain urokinase (scu-PA) which enhances
25 fibrinolysis by converting plasminogen to plasmin which in turn degrades the fibrin clot,

(2) Antithrombin III (ATIII), which inhibits thrombin and Factor Xa; Tissue Factor Pathway Inhibitor (TFPI), which inhibits Factor Xa; and Thrombomodulin,
30 which activates Protein C, which, once activated, destroys Factor Va and Factor VIIa, all of which inhibit blood coagulation.

Proteins that inhibit platelet aggregation may also be linked to the promoters of this invention for the purpose
35 of inhibiting thrombogenesis.

Conversely, the blood coagulation pathway can also be affected by the vascular endothelial cell-

specific expression of proteins such as Factor VIII and Factor V which enhance clot formation, i.e., increase coagulation, thereby allowing the treatment of hemophilia and related diseases.

5 Treatment of the above described conditions by expression of such proteins can be accomplished by injection of an expression vector of the VEGF receptor promoter operably linked to the genes encoding the proteins described above. The method of injection can be
10 by bolus or localized injection by catheter and the like.

Construction of expression vectors containing the novel promoter sequences, such as the Flt-1 promoter sequence and its substantially homologous complements, 15 operably linked to DNA sequence encoding a gene product and capable of expressing said gene product when transfected into a target host cell can be accomplished by methods known to one of skill in the art. Typically the promoter and the DNA sequence encoding the desired 20 gene product will be cloned into an expression vector via suitable restriction endonuclease sites such that the promoter is upstream of and in-frame with the DNA sequence. The expression vector may be a plasmid, virus or a cosmid. The cloned expression vector may then be 25 transfected into the target host cells and successfully transformed cells may be selected based on the presence of a suitable marker gene as described earlier.

Endothelial cell specificity of the Flt-1 promoter was shown by transfection of the 5'-deletion 30 mutants described above into murine fibroblast NIH-3T3 cells and HFF cells and comparing luciferase activity to BAEC transfected cells. As shown in Fig. 4, relative luciferase activities in NIH-3T3 and HFF cells were much weaker than those in BAEC. The endothelial specificity 35 of the Flt-1 promoter was further demonstrated by transfection of the 5'-deletion mutants into various human primary cells. The Flt-1 promoter

(-748/+284)-luciferase-fusion gene construct was introduced into human cells using a replication-deficient recombinant adenovirus. The recombinant adenovirus AdexFLTP-luc carrying the *Flt-1* promoter 5 (-748/+284)-luciferase-fusion gene was used to infect various human primary cells and established cell lines. Following infection, relative luciferase activities seen in human primary endothelial cells such as aortic endothelial cells, pulmonary arterial endothelial cells, 10 umbilical vein endothelial cells, and bovine adrenal endothelial cells were much higher than activities seen in human primary mammary epithelial cells, human primary aortic smooth muscle cells, NCI-H292 cells, human foreskin fibroblasts, rat primary aortic smooth muscle 15 cells, and NIH-3T3 cells (Fig. 5). These results showed that the *Flt-1* promoter region between positions -748 and +284 (residues 447 to 1479 of SEQ ID NO:1) conferred endothelial-specific gene expression.

Thus this invention provides compositions for 20 and methods of endothelial-specific tissue expression of heterologous DNA. Such endothelial-specific gene expression is useful in the study of and therapy for diseases involving the vascular system, e.g., hemostasis, wound healing, atherosclerosis, hypertension, diabetic 25 retinopathy, rheumatoid arthritis, blood cell trafficking, inflammatory conditions and tumor angiogenesis. The heterologous DNA may encode for proteins, polypeptides, hormones, antisense mRNA and the like. The proteins and polypeptides that may be 30 expressed include cellular adhesion molecules, cytokines, hormones, growth factors, enzymes, clotting factors, apolipoproteins, receptors, drugs, inhibitors of intra- and extra-cellular processes, antigens and oncogenes. Specific examples include TNF α , IL-2, granulocyte 35 macrophage colony stimulating factor (GM-CSF), insulin like growth factor, tissue plasminogen activator, mutant VEGF receptors and the like. Thus, this invention

provides methods of selective targeting and expression of such antitumor agents such as IL-2 and TNF α directly to cancerous tissue thus directly activating cytotoxic lymphocytes at the tumor site. Endothelial cell 5 specific-transcription of antisense mRNA against Flt-1 may be employed to inhibit and prevent VEGF receptor expression, thus preventing tumor angiogenesis and tumor growth. Alternatively, endothelial specific expression of soluble VEGF receptor mutants capable of binding VEGF 10 but incapable of stimulating endothelial cell mitogenesis such as those described in WO 94/21679 provides a specific method of controlling tumor proliferation and inhibiting tumor angiogenesis.

Host cells provided by this invention 15 expressing heterologous genes under the control of the promoter sequences of this invention can be used to produce proteins, preferably human proteins and fragments thereof. The process involves culturing the transformed cell under conditions wherein the protein is expressed, 20 optionally by inducing the activity of the promoter, and purifying the protein from the cell culture. Purification generally involves the steps of cell lysis, homogenization, centrifugation and separation of the desired protein by processes such as salt fractionation, 25 precipitation, and a variety of chromatographic methods such as anion exchange chromatography, hydrophobic interaction chromatography, high resolution chromatography, gel filtration chromatography and the like.

30 Drug Screening

Another aspect of this invention is its use in screening for pharmacologically active agents that modulate of VEGF receptor promoter activity, particularly for receptors of the type III subclass, and more 35 particularly, Flt-1, either by affecting signal transduction pathways that necessarily precede

transcription or by directly affecting transcription of the VEGF receptor.

For screening purposes an appropriate host cell, preferably an endothelial cell, more preferably a 5 vascular endothelial cell, is transformed with an expression vector comprising a reporter gene operably linked to the VEGF receptor promoter of this invention. The transformed host cell is exposed to various test substances and then analyzed for expression of the 10 reporter gene. This expression can be compared to expression from cells that were not exposed to the test substance. A compound which increases the promoter activity of the VEGF receptor promoter will result in increased reporter gene expression relative to the 15 control. Similarly, compounds which act as antagonists for the VEGF receptor signalling pathway will result in decreased reporter gene expression relative to the control.

Thus in one aspect of the invention one can 20 screen for test compounds that regulate the activity of the VEGF receptor promoter by:

(a) contacting a host cell in which the VEGF receptor promoter disclosed herein is operably linked to a reporter gene with a test medium containing the test 25 compound under conditions which allow for expression of the reporter gene;

(b) measuring the expression of the reporter gene in the presence of the test medium;

(c) contacting the host with a control medium 30 which does not contain the test compound but is otherwise identical to the test medium in (a), under conditions identical to those used in (a);

(d) measuring the expression of reporter gene in the presence of the control medium; and

35 (e) relating the difference in expression between (b) and (d) to the ability of the test compound to regulate the activity of the VEGF receptor promoter.

Alternatively, the transformed cells may be induced with a transcriptional inducer, such as IL-1 or TNF α , forskolin, dibutyryl-cAMP, or a phorbol-type tumor promoter, such as, for example PMA. Transcriptional activity is measured in the presence or absence of a pharmacologic agent of known activity (i.e., a standard agent) or putative activity (i.e., a test agent). A change in the level of expression of the reporter gene in the presence of the test agent is compared to that effected by the standard agent. In this way, the ability of a test agent to affect VEGF receptor transcription and their relative potencies can be determined.

Thus one aspect of this invention provides methods of measuring the ability of a test compound to modulate VEGF receptor transcription by:

(a) contacting a host cell in which the VEGF receptor promoter disclosed herein is operably linked to a reporter gene with an inducer of VEGF receptor promoter activity under conditions which allow for expression of the reporter gene;

(b) measuring the expression of the reporter gene in the absence of the test compound;

(c) exposing the host cells to the test compound either prior to, simultaneous with, or after contacting, the host cells with the inducer;

(d) measuring the expression of the reporter gene in the presence of the test compound; and

(e) relating the difference in expression between (b) and (d) to the ability of the test compound to modulate VEGF receptor transcription.

Since different inducers are known to affect different modes of signal transduction (e.g., cAMP responsive, calcium ion responsive), it is possible to identify with greater specificity compounds which affect a particular signal transduction pathway. Furthermore, since the VEGF receptors, particularly Flt-1, has been shown to be upregulated in tumor cells and this upregulation is

necessary for tumor angiogenesis, such assays provide a means of identifying compounds which will inhibit and/or reverse tumor growth by downregulating Flt-1 and thus preventing tumor angiogenesis.

5 In another aspect of this invention, transgenic animals expressing a heterologous gene encoding a detectable product under the regulatory control of the VEGF receptor promoter disclosed herein may be used to determine the effect of a test compound on the 10 stimulation or inhibition of the VEGF receptor promoter. The test compound is administered to the animal and the degree of expression of the heterologous gene observed is compared to the degree of expression in the absence of administration of the test compound using routine 15 bioassays as disclosed herein.

A variety of reporter genes may be used. Preferred are those which produce a protein product that is easily measured in a routine assay. Suitable reporter genes include but are not limited to chloramphenicol 20 acetyl transferase, luciferase and β -galactosidase. Convenient assays are colorimetric, fluorimetric and enzymatic assays. Most preferred are reporter genes that are expressed within the cell and whose extracellular products are directly measured in the intracellular 25 medium, or in an extract of the intracellular medium of a cultured cell line. This provides advantages over using a reporter gene whose product is secreted, since the rate and efficiency of the secretion introduce additional variables which complicate interpretation of 30 the assay.

The host cells transformed with the novel promoter sequences of this invention can also be used to identify compounds which specifically bind the VEGF receptor and act as agonists or antagonists of the VEGF 35 receptor. As described earlier, deletion constructs of the VEGF receptor promoter can be employed to increase

VEGF receptor expression and increase the sensitivity of the assay. This method comprises:

- (a) incubating a host cell transformed with a VEGF receptor promoter of SEQ ID NO: 1, or fragment thereof operably linked to a VEGF receptor with a test compound and a labelled VEGF;
- (b) measuring the amount of labelled VEGF which binds to the cell; and
- (c) comparing the amount bound in (b) to the amount of VEGF that binds to the cell in the absence of the test compound and relating the difference in these two amounts to the test compound being an antagonist or agonist of the VEGF receptor regulatory system.

15 Transgenic Animals

This invention also provides transgenic animals useful as disease models for studying VEGF receptor function and endothelial cell-specific gene expression.

Transgenic animals with genes comprising the VEGF receptor promoters operably linked to a heterologous gene can be prepared by methods known to those of skill in the art such as, but not limited to, B. Hogan et al, Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, New York (1986) and U.S. Patent No. 5,162,215, R. A. Bosselman et al, Method of Gene Transfer into Chickens and other Avian Species (1992).

Briefly, using mice as an example, fertilized eggs are collected by washing out the oviducts of mated females and a DNA construct of the VEGF receptor promoter operably linked to a heterologous DNA sequence is microinjected into the pronuclei. The injected eggs are then transferred to and implanted in the uterus of foster mothers, female mice made pseudopregnant by mating with vasectomized males. After birth the progeny mice are checked for presence of the transgene by Southern blotting of DNA extracted from a small piece of the tail. If suitable primers are available, screening can be

rapidly performed by polymerase chain reaction. The transgene may be integrated into the germ line cell, somatic cells or both. Transgenic mice carrying the transgene in their germ line cells can be identified by 5 mating them with normal nontransgenic mice and determining whether the inheritance of the transgene follows expected Mendelian genetics. This is often conveniently accomplished by including in the injected DNA construct a gene coding for readily visible trait 10 such as skin coat color. An alternative method of transgenic animal production involves injecting a DNA construct comprising the novel VEGF receptor promoters of this invention into undifferentiated embryonic stem cells prior to injecting into the mouse blastocyst.

15 Such transgenic animals provide an animal model for human diseases. This is particularly important for modelling diseases where no good animal model exists because the pathogen is specific for a human host. Endothelial cell-specific gene expression of 20 pharmacologically active proteins in transgenic animals allows one to study and identify therapeutically agents for the treatment of human disease in an animal model. The animals carrying genes comprising the VEGF receptor promoter sequences disclosed herein can be used to test 25 for compounds which modulate gene expression in vivo, in particular by regulating the promoter activity of the VEGF receptor. As described earlier, vascularization of solid tumor masses are characterized by upregulation and increased expression of the VEGF receptor, particularly 30 Flt-1. Thus such transgenic animals may be used to identify compounds which reverse this upregulation.

Introduction of the desired DNA sequence at the fertilized oocyte stage ensures that the transgene is present in all of the germ cells and somatic cells of the 35 transgenic animal and has the potential to be expressed in all such cells. The presence of transgene in the germ cells of the transgenic "founder" animal means that all

of its progeny will in turn carry the transgene in all of their germ line and somatic cells. Conversely, introduction of the transgene at a later embryonic stage in a founder animal may result in limited presence of the 5 transgene in some somatic cell lineages of the founder animal. Chimeric animals in which fewer than all of the somatic and germ cells contain the transgenic DNA sequence of the present invention, produced for example, when fewer than all of the cells of the morula are 10 transfected in the process of producing the transgenic animal are also within the scope of the present invention.

Transgenic animals may also be used as bioreactors for the production of large amounts of a 15 desired protein. Production of certain physiologically active proteins which require unique glycosylation patterns for correct folding and processing may require their expression in specific mammalian cells. In particular, the promoter sequences of this invention may 20 be used to direct the production of a heterologous gene operably linked to the promoter in endothelial cells.

EXAMPLES

The following examples are given to enable 25 those of skill in the art to more clearly understand and practice the invention. They should not be considered as limiting the scope of the invention, but merely illustrative and representative thereof.

Materials

30 The recombinant adenovirus Adex1CA lacZ, the adenovirus cosmid vector pAdex1W and EcoT22I-digested adenoviral DNA - terminal protein complex (TPC) were prepared as described in Y. Nakamura et al., *Cancer Research*, 54, 5757-5760 (1994).

35 Bovine adrenal endothelial cells (BAEC) were obtained from Dr. Richard Weiner at University of California, San Francisco, and maintained in Dulbecco's

modified essential medium (DMEM) supplemented with 1 mg/ml glucose, 1 ng/ml bFGF (basic fibroblast growth factor), and 10% fetal bovine serum (FBS). Human umbilical vein endothelial cells (HUVEC), human aortic 5 endothelial cells (HAEC), human pulmonary arterial endothelial cells (HPEC), human aortic smooth muscle cells (AOSMC), and human mammary epithelial cells (HMEC) were obtained from Clonetics and maintained according to the manufacturer's recommendation. NIH-3T3 cells and 10 human foreskin fibroblasts (HFF) were maintained in DMEM (Dulbecco's modified essential medium) supplemented with 10% FBS. NCI-H292 human pulmonary mucoepidermoid carcinoma cells were maintained in RPMI 1640 supplemented with 10% FBS. Rat aortic smooth muscle cells 15 (Sprague-Dawley rats) were isolated from explants as described by Ross, R. (1971) *J. Cell Biol.*, **50**, 172-186 and maintained in DMEM supplemented with 10% FBS.

Abbreviations

dNTPs, dNTP mix, deoxynucleotide triphosphates; 20 HUVEC, human umbilical vein endothelial cells; BAEC, bovine adrenal endothelial cells; HAEC, human aortic endothelial cells; HPEC, human pulmonary arterial endothelial cells; AOSMC, human aortic smooth muscle cells; HMEC, human mammary epithelial cells; HFF, human 25 foreskin fibroblast; TPC, terminal protein complex; CAT, chloramphenicol acetyltransferase; CREB, cAMP response element binding protein; ATF, activating transcription factor; IBMX, 3-isobutryryl-1-methylxanthine; DMEM, Dulbecco's modified essential medium; FBS, fetal bovine 30 serum; bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; AMV, avian myeloblastosis virus; kb, kilobase pairs; bp, base pairs; PBS, phosphate buffered saline; DTT, dithiothreitol.

EXAMPLE 1

Cloning of the 5'-flanking Region of the Human Flt-1 Gene

A human placenta genomic library in EMBL-3 phage (Clontech, Palo Alto, CA) was screened with a 600 bp *Eco*RI/*Acc*I fragment from the 5' end of the *Flt-1* cDNA. (Peters, K. G., De Vries, C., and Williams, L. T. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 8915-8919; De Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992) *Science* **255**, 989-991 and M. Shibuya et al., Oncogene, **5**, 519 (1990)). After three rounds of screening, 13 positive clones were isolated. Two sets of overlapping synthetic oligonucleotides, 5'-GGACACTCCTCTGGCTCCTCCCCGGCAGCGGCCGGCTCGG-3' (oligo-E) (SEQ ID NO:3) and 5'-CGCTGGCCGCTGCACCCGAGCCCCGGAGCCCGCTCCGAGCCGCCGC-3' (oligo-F) (SEQ ID NO:4), corresponding to the 5' end of the *Flt-1* cDNA between positions +3 and +79 (designated as probe R or b) and 5'-GGTCTTGCCCTGAAATGGTGAGTAAGGAAAGCGAAAGGCTGAGCATAACT-3' (oligo-J) (SEQ ID NO:5) and 5'-CAGAATTGTTGCCATTCTTCCACAGGCAGATTAGTTATGCTCAGCCT-3' (oligo-K) (SEQ ID NO:6) corresponding to the sequence of the *Flt-1* cDNA between positions +427 and +502 (designated as probe B) were annealed, followed by filling-in with Klenow fragment in the presence of [α -³²P]dCTP. Four of the 13 clones hybridized with probe A, but not with probe B. In contrast, the other clones hybridized with probe B, but not with probe A. Three different clones which hybridized with probe A were selected for restriction endonuclease and Southern blot analyses. The restriction maps of these clones were determined by the partial restriction method and is shown in Fig. 1. The 3 kb *Eco*RI/*Xba*I fragments from all three clones and a 7 kb *Eco*RI fragment from clone #5-11 were subcloned into Bluescript KS+ (Stratagene, La Jolla, CA) to generate pBKS3.0 and pBKS7.0. These plasmids were

used for further restriction enzyme mapping, nucleotide sequencing analysis, subcloning, and expression studies as described below.

Detailed restriction maps and partial sequences 5 showed that these 3 kb fragments were identical. The nucleotide sequence of a 1.8 kb *Bst*XI/*Xho*I fragment from clone #4-18 (Fig. 1) was determined by the Sanger dideoxy termination method. This fragment contains exon 1, a 5' portion of intron 1, and the 5' flanking region of Flt-1 10 containing putative transcription factor binding sites such as a TATA box, a CREB/ATF element, and an Ets binding site (Fig. 2). The first intron contains a putative transcription arrest site as discussed below.

Transcription Initiation Site - To identify the 15 transcription initiation site of Flt-1, primer-extension analysis was performed with total RNA from HUVEC and human lung tissue (Fig. 3). The transcription initiation site was mapped to an adenine residue 25-bp down-stream from the TATA box. This result was confirmed by S1 20 mapping analysis (data not shown).

Primer Extension and S1 Mapping - Primer extension analysis was carried out according to described methods (Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold

25 Spring Harbor Laboratory, Cold Spring Harbor, NY). Briefly, oligo-F was end-labeled with T4 polynucleotide kinase. Approximately 5 ng of labeled primer was hybridized to 50 mg of total RNA from HUVEC, human lung tissue (Clontech, Palo Alto, CA), and yeast tRNA in 30 Hybridization buffer (80% formamide/40 mM PIPES (pH 6.4)/400 mM NaCl/1 mM EDTA) at 30°C overnight. The extension reaction was carried out with 50 units of AMV reverse transcriptase (Promega, Madison, WI) in 50 mM Tris-HCl (pH 7.6)/60 mM KCl/10 mM MgCl₂/1 mM dNTPs/1 mM 35 dithiothreitol/1 U/ml RNAase Block (Stratagene)/50 mg/ml actinomycin D for 2 h at 37 °C. The extended products were analyzed on denaturating 6% gel polyacrylamide gels.

Sequence reactions on Flt-1 with the same primer were run in parallel for accurate determination of the extension termination site.

S1 mapping analysis was carried out as described 5 Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1987) Current Protocols in Molecular Biology (Wiley, New York), 4.6.1-4.6.13. Briefly, end labeled oligo-F was hybridized with pBKS3.0 and incubated with 4 units of 10 Klenow fragment in the presence of 4 mM dNTPs for 30 min at 37°C. After heat inactivation, the extended product was digested with SmaI, separated on an alkaline agarose 15 gel, and purified by phenol extraction and ethanol precipitation. The probe (5 x 10⁴ Cerenkov counts) was then hybridized to 50 mg of total RNA from HUVEC, human 20 lung tissue (Clontech), or yeast tRNA in Hybridization buffer at 30 °C overnight. The reaction mixture was digested with 300 U of S1 nuclease in 280 mM NaCl/50 mM sodium acetate (pH 4.5)/4.5 mM ZnSO₄ for 60 min at 30 °C. The protected products were analyzed on denaturating 6% polyacrylamide gels.

EXAMPLE 2

Construction of Deletion mutant plasmids of the Flt-1 promoter

25 and Luciferase fusion genes
Construction of p(-2.5k/+284)-luc Containing the 5'-flanking Region of Flt-1 and Luciferase-fusion Gene - The plasmid pMC-luc was generated by cloning annealed complementary oligonucleotides including restriction 30 sites for *Swa*I, *I-Ppo*I, *Pme*I, *Sma*I, *Asc*I, *Not*I, *Xho*I, *Srf*I, *Sfi*I, and *Hind*III (5'-ATTTAAATCTCTTAAGGTAGCGTTAAACCCGGCGCGCCGGCGCT CGAGCCCGGGCGCTCACTGGCCATTAAATA-3' (SEQ ID NO:7) and 35 5'-AGCTTATTAAATGCCAGTGAGGCCCGGGCTCGAGCGGCCGGCG into the *Sma*I and *Hind*III sites of a luciferase expression vector (pGL2-basic, Promega). A 3 kb

NotI/XhoI fragment from pBKS3.0 which contains the 5'-flanking region, the first exon, and part of the first intron of Flt-1 was inserted into the NotI and XhoI sites of pMC-luc to generate p(-2.5k/+550)-luc. A 3 kb 5 SacI/KpnI fragment from pBKS3.0 was inserted into the KpnI and SacI sites of pGL2-basic to generate p(+550/-2.5k)-luc which contains the 5'-flanking region oriented in the reverse direction. The plasmid p(-2.5k/+284)-luc, in which most of the first intron was 10 deleted, was constructed by digesting p(-2.5k/+550)-luc with NcoI, XhoI and Mung-Bean nuclease followed by self-ligation.

Construction of 5'-deletion Mutant Plasmids - The plasmid p(-1.9k/+284)-luc was constructed by digesting 15 p(-2.5k/+284)-luc with PstI followed by self-ligation. The plasmid p(-1195/+284)-luc was constructed by digesting p(-2.5k/+284)-luc with PstI, BstXI, treating with T4 DNA polymerase, and self-ligating. To generate a series of deletion mutants, the plasmid 20 p(-2.5k/+284)-luc was treated with BstXI, T4 DNA polymerase, and PstI, and digested with exonuclease III from 5'-end followed by self-ligation using Erase-a-Base kit (Promega). Several 5'-deletion mutants were produced: p(-962/+284)-luc, p(-748/+284)-luc, 25 p(-583/+284)-luc, p(-386/+284)-luc, p(-356/+284)-luc, (-333/+284)-luc, p(-239/+284)-luc, p(-219/+284)-luc, and p(+151/+286)-luc. To construct another deletion mutant, p(-2.5k/+284)-luc was digested with AatII and PstI, treated with T4 DNA polymerase, and then self-ligated to 30 generate p(-75/+284)-luc.

Construction of Luciferase-fusion Plasmids Containing a 5'-flanking Region, Exon 1, and a Hybrid Intron - The plasmid p(-2.5k/+550)sp-luc which contains a hybrid intron composed of the 5' portion of the first intron of 35 Flt-1 and the 3' portion of mouse immunoglobulin heavy chain gene (Bothwell, A. L. M., Paskind, M., Reth, M., Imanishi-Kari, T., Rajewsky, K., and Baltimore, D. (1981)

Cell 24, 625-637) was constructed by cloning annealed complementary oligonucleotides corresponding to a mouse immunoglobulin heavy chain variable region (5'-TCGAGGCTTGAGGTCTGGACATATACATGGGTGACAATGACATCCACTTG 5 CCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAATGCAG-3' (SEQ ID NO:9) and 5'-CTGCAGTTGGACCTGGAGTGGACACCTGTGGAGAGAAAGGCAAAG TGGATGTCATTGTCACCCATGTATATGTCCAGACCTCAAGCC-3') (SEQ ID NO:10) into the *Xho*I and *Srf*I sites of p(-2.5k/+550)-luc. The resulting plasmid p(-2.5k/+550)sp-luc was treated 10 with *Xho*I, Klenow fragment, and *Nco*I and ligated with a 4 kb *Nco*I/*Eco*R1 fragment from pBKS7.0 which contains the 5' portion of the first intron of Flt-1.

Construction of CREB/ATF Element-deleted Mutant Plasmids
- The plasmid p(-962/+284)-luc was digested with *Aat*II 15 and treated with T4 DNA polymerase, resulting in pΔCRE(-962/+284)-luc. Four internal bases of CREB/ATF element (ACGT out of TGACGTCA) were deleted in pDCRE(-962/+284)-luc.

EXAMPLE 3

Preparation of Transfected Cells and Enzyme Assays

For transfection analyses, the plasmids described in Example 2 were purified with Wizard Megaprep (Promega) followed by cesium chloride gradient ultracentrifugation. BAEC and NIH-3T3 cells were seeded 25 onto 6-well plates or, for HFF, onto 100 mm dishes at a density adjusted so that they reached 40 - 60% confluence prior to transfection. For BAEC and NIH-3T3 cells, 5 mg DNA of test plasmid, 5 mg of pSV-CAT (pCAT-promoter, Promega), and 10 ml (5 ml for NIH-3T3 cells) of 30 lipofectin (GibcoBRL) were incubated in 0.1 ml OptiMEM (GibcoBRL) for 20 min. Similarly, for HFF, 25 mg plasmid construct DNA and 5 mg DNA of pSV-CAT, and 50 ml of lipofectin were incubated in 0.4 ml of OptiMEM. The resulting transfection mixture was added to the medium 35 and incubated for 6 - 10 h at 37 °C. Then, the medium was replaced by complete medium for an additional 3 days. For the stimulation experiments, 10 mM forskolin and 0.5

mM 3-iso-butyryl-1-methyl-xanthine (IBMX) or 0.5 mM dibutyryl-cAMP and 0.5 mM IBMX were added directly to media 16 - 17 h prior to harvest. Cells were washed with ice-cold PBS twice, and lysed with 80 ml (6-well plate) 5 or 400 ml (10 cm dish) of 100 mM potassium phosphate (pH 7.8)/0.5% Triton X-100. After removing the insoluble cell debris by centrifugation, each cell lysate was used to measure luciferase and CAT activities. The luciferase activity was measured with a Monolight 2010 luminometer 10 in the presence of 1 mM DTT using Luciferase Assay Reagent (Promega). CAT activity was determined by the phase-extraction procedure using [³H]chloramphenicol (Du Pont-New England Nuclear) and xylenes after endogenous deacetylating activity was destroyed by heating the 15 lysates for 10 min at 65 °C (Seed, B. and Sheen, J.-Y. (1988) Gene (Amst.) **67**, 271-277). The efficiency of transfections was normalized with activities of CAT assay.

Results are shown in Figures 4 and 6A (5'- 20 deletion mutants) and Figure 6B (CREB/ATF deletion mutant). Deletion mutant p(-748/+248)-luc showed the highest activity. Transfection of the series of constructs deleted from -2.5 kb to +151 suggested the presence of at least two regions, 2500 to -1195 and -356 25 to -333, containing negative regulatory sequences, and two regions, -748 to -583 and -239 to -75, containing positively regulatory sequences. Deletion to +151 decreased luciferase activity to the level of the promoterless plasmid pMC-luc. Deletion of 4 internal 30 bases in the CREB/ATF element of the *flt-1* promoter (ACGT out of TGACGTCA) diminished relative luciferase activity in BAEC by 85% (Fig. 6B). However, it was not possible to detect any stimulation of luciferase activity in response to forskolin/IBMX and dibutyryl-cAMP/IBMX in BAEC 35 transfected with either p(-962/+284)-luc or pDCRE(-962/+284)-luc (data not shown). Therefore, the CREB/ATF element of the *Flt-1* promoter is important for

basal transcription of Flt-1, but may not be important in the transcriptional activation in response to cAMP elevation.

The First Intron of *flt-1* Negatively Regulated
5 Transcription - Transfection of the p(-2.5k/+550)-luc construct, which contains 220 bp of the first intron of *flt-1* (containing the 5' splice site but not the 3' splice site), resulted in no luciferase activity (Fig. 7). This may be due to the production of an undesirable
10 protein instead of luciferase since the first intron contains an ATG at +286 which is up-stream of the initiation codon of the luciferase gene and may not be spliced out because of the lack of a 3' splice site. When a 3' splice site from a mouse immunoglobulin gene
15 (10) was introduced down-stream of the first intron to generate a hybrid intron (p(-2.5k/550)sp-luc), luciferase activity was partially restored. The idea to make this construct was based on results obtained with a hybrid intron consisting of a 5' splice site from the first exon
20 of the adenovirus tripartite leader and a 3' splice site from a mouse immunoglobulin gene on pMT2 expression vector (Kaufman, R. J., Davies, M. V., Pathak, V. K., and Hershey, J. W. B. (1989) *Mol. Cell. Biol.* **9**, 946-958). These studies showed that the hybrid intron was
25 completely spliced out when eukaryotic initiation factor 2 was expressed on pMT2 vector. Thus, it appears likely that the decrease of luciferase activity seen in p(-2.5k/550)sp-luc (Fig. 7) does not result from a deficiency in splicing. Therefore, it was concluded that
30 the first intron of *flt-1* negatively regulated the transcription.

EXAMPLE 4

Preparation of Transfected Cells with the Flt-1 promoter using Viral Vectors and Enzyme Assays

Construction of a recombinant adenovirus containing the Flt-1 promoter - luciferase fusion gene and enzyme assays

5 - The plasmid p(-748/+284)-luc was digested with *Sal*I, treated with T4 DNA polymerase, and digested with *Bam*HI to generate a 3.7 kb fragment. The fragment was cloned into the *Swa*I site of pAdex1W adenovirus cosmid vector,

10 10 Y. Nakamura et al., *Cancer Research*, **54**, 5757-5760 (1994), to generate pAdexFLTP-luc. pAdexFLTP-luc and the EcoT22I-digested adenoviral DNA-TPC were co-transfected into 293 cells to prepare a replication-negative recombinant adenovirus AdexFLTP-luc (Kanegae, Y.,

15 Makimura, M., and Saito, I. (1994) *Jpn. J. Med. Sci. Biol.*, **47**, 157-166). A recombinant adenovirus Adex1CALacZ which contains a CAG promoter (modified chicken b-actin promoter with CMV-IE enhancer) (Niwa, H., Yamamura, K., and Miyazaki, J. (1991) *Gene*, **108**, 193-200)

20 and a b-galactosidase gene and AdexFLTP-luc were used to co-infect with various cell lines (HAEC, HPEC, HUVEC, BAEC, HMEC, AOSMC, NCI-H292, HFF, RASMC, and NIH-3T3). Briefly, AdexFLTP-luc (1.1×10^5 pfu/ml) and AdexCA1LacZ (8.4×10^4 pfu/ml) were incubated with cells in 0.5 ml of

25 DMEM supplemented with 10% FBS in 24-well plates. Luciferase activity was measured as described above and b-galactosidase activity was measured with chlorophenol red b-D-galactopyranoside (Boehringer Mannheim Biochemica). The efficiencies of transfections were

30 normalized with activities of b-galactosidase assays. Results are shown in Fig. 5 and demonstrate that the Flt-1 promoter region between positions -748 and +284 conferred endothelial-specific gene expression.

Although the foregoing invention has been described in some detail by way of illustration and example for the purposes of clarity and understanding, it will be obvious that certain changes and modifications

may be practiced within the scope of the appended claims. All patents, patent applications and publications described herein are herewith incorporated by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: The Regents of the University of California

(ii) TITLE OF INVENTION: Novel Promoter for VEGF Receptor

(iii) NUMBER OF SEQUENCES: 10

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Robbins, Berliner & Carson
(B) STREET: 201 N. Figueroa Street, 5th Floor
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90012-2628

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Berliner, Robert
(B) REGISTRATION NUMBER: 20,121
(C) REFERENCE/DOCKET NUMBER: 5555-410

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 213-977-1001
(B) TELEFAX: 213-977-1003

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1745 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1..1195
 (D) OTHER INFORMATION: /note= "Nucleotides numbered 1 through 1195 correspond to -1195 through -1 from Figure 2."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTTGGCAACTT	TGGGTTACCC	AACCTTCCTA	GGCGGGGAGG	TAGTCCAGTC	CTTCAGGAAG	60
AGTCTCTGGC	TCCGTTCAAG	AGCCATACA	GTCCCTTGTA	TTACATCCCT	CTGACGGGTT	120
CCAATAGGAC	TATTTTCAA	ATCTGCGGTA	TTTACAGAGA	CAAGACTGGG	CTGCTCCGTG	180
CAGCCAGGAC	GACTTCAGCC	TTTGAGGTAA	TGGAGACATA	ATTGAGGAAC	AACGTGGAAT	240
TAGTGTCTATA	GCAAATGATC	TAGGGCCTCA	ACTTAATTTC	AGCCGGTTGT	GGTCAGAGTC	300
ACTCATCTTG	AGTAGCAAGC	TGCCACCAGA	AAGATTTCCTT	TTTCGAGCAT	TTAGGGAATA	360
AAAGTTCAAGT	GCCCTGCCT	TCCAAGTTGC	AGGAGCAGTT	TCACGCCCTCA	GCTTTTTAAA	420
GGTATCATAA	TGTTATTCT	TGTTTTGCTT	CTAGGAAGCA	GAAGACTGAG	AAATGACTT	480
GGGCAGGGTGC	ATCAATGCGG	CCGAAAAAGA	CACGGACACG	CTCCCTGGG	ACCTGAGCTG	540
GTTCGCAGTC	TTCCCAAAGG	TGCCAAGCAA	GGTCAGTTC	CCCTCAGGGC	CTCCAGGTT	600
AGTGCCCTGT	GCCGAGGGTC	TCCGGTGCTC	TCCTAGACTT	CTCGGGACAG	TCTGAAGGGG	660
TCAGGAGCGG	CGGGACACCG	CGGAAAGAGC	AGGCAAGGGG	AGACAGCCGG	ACTGCCCTC	720
AGTCCTCCGT	GCCAAGAAC	CCGTCGCGGA	GGCGCGGCCA	GCTTCCCTTG	GATCGGACTT	780
TCCGCCCTA	GGGCCAGGGC	GCGGAGCTTC	AGCCTTGTC	CTTCCCCAGT	TTCGGGCGGC	840
CCCCAGAGCT	GAGTAAGCCG	GGTGGAGGGA	GTCTGCAAGG	ATTTCTGAG	CGCGATGGGC	900
AGGAGGAGGG	GCAAGGGCAA	GAGGGCGCGG	AGCAAAGACC	CTGAACCTGC	CGGGGCCCGC	960
CTCCCGGGCC	CGCGTCGCCA	GCACCTCCCC	ACCGCGCGTC	GGCCCGGGC	CACCCGCCCT	1020
CGTGGCCCCC	CGCCCTCTC	CGTAGCCGCA	GGGAAGCGAG	CCTGGGAGGA	AGAAGAGGGT	1080
AGGTGGGGAG	GCGGATGAGG	GGTGGGGAC	CCCTTGACGT	CACCAAGAAGG	AGGTGCCGGG	1140
GTAGGAAGTG	GGCTGGGAA	AGGTTATAAA	TGCCCCCGC	CCTCGGTGC	TCTTCATCGA	1200
GGTCCGCGGG	AGGCTCGGAG	CGCGCCAGGC	GGACACTCCT	CTCGGCTCT	CCCCGGCAGC	1260
GGCGGGCGGCT	CGGAGCGGGC	TCCGGGGCTC	GGGTGCAGCG	GCCAGCGGGC	GCCTGGCGGC	1320
GAGGATTACC	CGGGGAAGTG	GTTGTCTCT	GGCTGGAGCC	GCGAGACGGG	CGCTCAGGGC	1380
GCGGGGCCGG	CGGCGCGCAA	CGAGAGGACG	GAECTGGCG	GGCGGGCTT	TGGCCGCGGG	1440
GAGCGCGGGC	ACCGGGCGAG	CAGGCCCGCT	CGCGCTCACC	ATGGTCAGCT	ACTGGGACAC	1500
CGGGGTCTG	CTGTCGCCGC	TGCTCAGCTG	TCTGCTCTC	ACAGGTGAGG	CGGGCTGGG	1560

50

GGCCGGGGCC	TGAGGCGGGC	TGCGATGGGG	CGGCCGAGG	GCAGAGCCTC	CGAGGCCAGG	1620
GCGGGGTGCA	CGCGGGGAGA	CGAGGCTGTA	GCCCAGGAGAA	GCTGGCTACG	GCGAGAACCT	1680
GGGACACTAG	TTGCAGCGGG	CACGCTTGGG	GCCGCTGCC	CCTTCTCCG	AGGGAGCGCC	1740
TCGAG						1745

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGGGGCTCCG	TTGCCAGGGT	TCTGT	25
------------	------------	-------	----

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGACACTCCT	CTCGGCTCCT	CCCCGGCAGC	GGCGGCGGCT	CGG	43
------------	------------	------------	------------	-----	----

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGCTGGCCGC	TGCACCCGAG	CCCCGGAGCC	CGCTCCGAGC	CGCCGC	46
------------	------------	------------	------------	--------	----

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGTCTTGCC TGAAATGGTG AGTAAGGAAA GCGAAAGGCT GAGCATAACT

50

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CAGAATTGTT TGCCATTCT TCCACAGGCA GATTTAGTTA TGCTCAGCCT

50

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 84 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATTTAAATCT CTCTTAAGGT AGCGTTAAA CCCGGGGCGG CGCGGGCCGC TCGAGCCCGG

60

CGGGCCTCAC TGGCCATTAA AATA

84

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 88 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AGCTTATTAA AATGGCCAGT GAGGCCGGCC GGGCTCGAGC GGCGCGGGCG CGCCCGGGTT

60

TAAACGCTAC CTTAAGAGAG ATTAAAT

88

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 92 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TCGAGGGCTTG AGGTCTGGAC ATATAATGG GTGACAATGA CATCCACTTT GCCTTTCTCT	60
CCACAGGTGT CCACTCCAG GTCCAATGCG AG	92

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 88 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (oligonucleotide)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTGCAGTTGG ACCTGGGAGT GGACACCTGT GGAGAGAAAG GCAAAGTGGA TGTCAATTGTC	60
ACCCATGTAT ATGTCCAGAC CTCAAGCC	88

WHAT IS CLAIMED IS:

1. A substantially purified nucleic acid molecule comprising a VEGF receptor promoter region.

5

2. The nucleic acid of Claim 1 wherein said VEGF receptor is a member of the receptor tyrosine kinase subclass type III family.

10

3. The nucleic acid of Claim 1 wherein said VEGF receptor is selected from the group consisting of Flt-1, Flk-1, and Flk-4.

15

4. The nucleic acid of Claim 1 wherein said nucleic acid further comprises a CREB/ATF element, at least one ETS-1 binding site and a nucleic acid sequence substantially homologous to the sequence between residues 447 and 1479 of SEQ ID NO: 1.

20

5. A nucleic acid molecule having a sequence selected from the group consisting of:

(a) a nucleic acid sequence substantially homologous to that of SEQ ID NO: 1, or a fragment thereof, exhibiting promoter activity;

25

(b) a nucleic acid sequence substantially complementary to said nucleic acid sequence of (a) or a fragment thereof;

30

(c) a nucleic acid sequence that hybridizes to said nucleic acid sequences of (a) or (b) or fragments thereof; and

(d) a nucleic acid identical to any of the sequences of (a), (b) or (c), with the proviso that any T may have been replaced by U.

35

6. The nucleic acid molecule of Claim 5 which is a DNA sequence.

7. An expression vector comprising the nucleic acid molecule of Claim 1.

5 8. The vector of Claim 7, wherein said vector is an expression vector operably linked to a heterologous gene encoding a gene product.

10 9. The vector of Claim 8, wherein said heterologous gene is a reporter gene.

15 10. The vector of Claim 8, wherein said heterologous gene is selected from the group consisting of IL-2, TNF α , tissue plasminogen activator, an antisense RNA corresponding to a gene encoding for a VEGF receptor or a fragment thereof, and a functionally defective VEGF receptor.

20 11. An expression vector comprising the nucleic acid sequence of SEQ ID NO: 1 or a fragment thereof.

25 12. A host cell transformed with the vector of Claim 8.

13. The host cell of Claim 12, wherein said host cell is a prokaryotic cell.

30 14. The host cell of Claim 12, wherein said host cell is a eukaryotic cell.

15. The host cell of Claim 14 which is a mammalian cell.

35 16. The host cell of Claim 15 which is a human cell.

17. The host cell of Claim 16 which is an endothelial cell.

18. The host cell of Claim 17 which is a tumor
5 cell.

19. A host cell transformed with the vector of
Claim 7.

10 20. A host cell transformed with the vector of
Claim 9.

21. An assay for screening for a test compound
that regulates the activity of a VEGF receptor promoter
15 comprising:

(a) contacting a host cell of Claim 20 with a
test medium containing said test compound under
conditions which allow for expression of said reporter
gene;

20 (b) measuring the expression of said reporter
gene in the presence of said test medium;

(c) contacting a host cell of Claim 20 with a
control medium which does not contain said test compound
but is otherwise identical to said test medium in (a),
25 under conditions identical to those used in (a);

(d) measuring the expression of reporter gene
in the presence of said control medium; and

(e) relating the difference in expression
between (b) and (d) to the ability of the test compound
30 to regulate the activity of the VEGF receptor promoter.

22. The method of Claim 21, wherein the
reporter gene is the luciferase gene.

35 23. The method of Claim 21, wherein the
reporter gene is the chloramphenicol acetyl transferase
gene.

24. The method of Claim 21, wherein the host cell is a mammalian cell.

25. The method of Claim 24, wherein the host 5 cell is an endothelial cell.

26. An assay for measuring the ability of a test compound to modulate VEGF receptor transcription comprising:

10 (a) contacting a host cell of Claim 20 with an inducer of VEGF receptor promoter activity under conditions which allow for expression of said reporter gene;

15 (b) measuring the expression of said reporter gene in the absence of the test compound;

(c) exposing the host cells to the test compound either prior to, simultaneous with, or after contacting, the host cells with the inducer;

20 (d) measuring the expression of said reporter gene in the presence of the test compound; and

(e) relating the difference in expression between (b) and (d) to the ability of the test compound to modulate VEGF receptor transcription.

25 27. The method of Claim 26, wherein the reporter gene is the luciferase gene.

28. The method of Claim 26, wherein the reporter gene is the chloramphenicol acetyl transferase 30 gene.

29. The method of Claim 26, wherein the host cell is a mammalian cell.

35 30. The method of Claim 29, wherein the host cell is an endothelial cell.

31. A method of determining whether a test compound is an antagonist or agonist of the VEGF/VEGF receptor regulatory system, the method comprising:

(a) incubating the host cell of Claim 12 wherein said gene product is a VEGF receptor with a test medium containing said test compound and a labelled VEGF under conditions which allow for binding of the labelled VEGF to the host cell;

5 (b) measuring the binding of labelled VEGF to said cell in the presence of the test compound;

(c) incubating the host cell of Claim 12 wherein said gene product is a VEGF receptor with a control medium which does not contain said test compound but is otherwise identical to the test medium in (a) and 15 a labelled VEGF, under conditions identical to (a);

(d) measuring the binding of labelled VEGF to said cell in the presence of the control medium; and

(e) comparing the binding of labelled VEGF in 20 (b) to the binding of labelled VEGF in (d) and relating the difference between the binding in (b) and the binding in (d) to the test compound being an antagonist or agonist of the VEGF/VEGF receptor regulatory system.

32. The method of Claim 31, wherein the host 25 cell is a mammalian cell.

33. The method of Claim 32, wherein the host cell is an endothelial cell.

30 34. A method for inhibiting angiogenesis of a tumor, which method comprises introducing a vector comprising the nucleic acid sequence of Claim 1, wherein said vector further comprises a gene encoding a protein, polypeptide, hormone, ribozyme or antisense RNA, which 35 decreases vascular permeability, operably linked to said nucleic acid sequence of Claim 1 into endothelial cells lining said tumor and expressing said gene.

35. A method for inhibiting angiogenesis of a tumor, which method comprises introducing a vector comprising the nucleic acid sequence of Claim 1, wherein said vector further comprises a gene encoding a protein, 5 polypeptide, hormone, ribozyme or antisense RNA, which has antimitogenic activity, operably linked to said nucleic acid sequence of Claim 1 into endothelial cells lining said tumor and expressing said gene.

10 36. A method for controlling angiogenesis in a mammal, said method comprising:

explanting cells from the mammal;
transfecting said cells with an expression vector comprising a nucleic acid of Claim 1 operatively linked to a gene coding a protein, polypeptide, hormone, 15 ribozyme or antisense RNA, which decreases vascular permeability or has antimitogenic activity;
selecting for cells which have incorporated and express said gene; and
20 reimplanting the cells into the mammal.

37. A transgenic or chimeric animal containing the vector of Claim 9.

25 38. A transgenic animal of Claim 37 which is a rodent.

30 39. A process for producing a host cell containing a heterologous gene operably linked to the promoter of Claim 1 which comprises:

(a) transfecting a cell with an expression vector comprising said heterologous gene operably linked to the promoter of Claim 1;
(b) simultaneously transfecting said cell with 35 a selectable marker gene; and
(c) selecting transformed host cells on the basis of said transformed cells containing the selectable

marker gene to produce said host cell containing a heterologous gene operably linked to the promoter of Claim 1.

5 40. A method for producing a gene product comprising culturing the host cells of Claim 12 under conditions wherein said gene product is produced and recovering the gene product from the cell culture.

10 41. The method of Claim 40, wherein said host cell is an endothelial cell.

1/8

FIG. 1




FIG. 2A

-1195 GTGGCAACTT TGGGTTACCC AACCTTCCTA GGCGGGGAGG TAGTCCAGTC
 -1145 CTTCAGGAAG AGTCTCTGGC TCCGTTCAAG AGCCATCACA GTCCCTTGTA
 -1095 TTACATCCCT CTGACGGGTT CCAATAGGAC TATTTTCAA ATCTGCGGTA
 -1045 TTTACAGAGA CAAGACTGGG CTGCTCCGTG CAGCCAGGAC GACTTCAGCC
 -995 TTTGAGGTAA TGAGACATA ATTGAGGAAC AACGTGGAAT TAGTGTCTA
 -945 GCAAATGATC TAGGGCCTCA AGTTAATTTC AGCCGGTTGT GGTCAAGAGTC
 -895 ACTCATCTG AGTAGCAAGC TGCCACCAAGA AAGATTTCTT TTTCGAGCAT
 -845 TTAGGGAATA AAGTTCAAGT GCCCTGCGCT TCCAAGTTGC AGGAGCAGTT
 -795 TCACGCCTCA GCTTTTAAA GGTATCATAA TGTTATTCCCT TGTTTGCTT
 -745 CTAGGAAGCA GAAGACTGAG GAAATGACTT GGGCGGGTGC ATCAATGCGG
 -695 CCGAAAAAGA CACGGACACG CTCCCCTGGG ACCTGAGCTG GTTCGCAGTC
 -645 TTCCCAAAGG TGCCAAGCAA GCGTCAGTTC CCCTCAGGCG CTCCAGGTT
 -595 AGTGCCTTGT GCCGAGGGTC TCCGGTGCCT TCCTAGACTT CTCGGGACAG
 -545 TCTGAAGGGG TCAGGAGCGG CGGGACAGCG CGGGAAAGAGC AGGCAAGGGG
 -495 AGACAGCCGG ACTGCGCCTC AGTCCTCCGT GCCAAGAACCA CCGTCGCGGA
 -445 GGC GCGGCCA GCTTCCCTG GATCGGACTT TCCGCCCTA GGGCCAGGCG
 -395 GCGGAGCTTC AGCCTTGTCC CTTCCCCAGT TTCGGGCGGC CCCCAGAGCT
 -345 GAGTAAGCCG GGTGGAGGGGA GTCTGCAAGG ATTTCTGAG CGCGATGGGC
 -295 AGGAGGAGGG GCAAGGGCAA GAGGGCGCGG AGCAAAGACC CTGAACCTGC
 -245 CGGGGCCGCG CTCCCGGGCC CGCGTCGCCA GCACCTCCCC ACGCGCGCTC
 -195 GGCCCCGGGC CACCCGCCCT CGTCGGCCCC CGCCCTCTC CGTAGCCGCA
 -145 GGGAAGCGAG CCTGGGAGGA AGAAGAGGGT AGGTGGGGAG GCGGATGAGG
 ets ets

-95 GGTGGGGAC CCCTTGACGT CACCAGAAGG AGGTGCCGGG GTAGGAAGTG
 CAEB/ATF ets

-45 GGCTGGGGAA AGGTTATAAA TCGCCCCCGC CCTCGGCTGC TCTTCATCGA
 ets TATA box

+6 GGTCCGGCGGG AGGCTCGGAG CGCGCCAGGC GGACACTCCT CTCGGCTCCT

+56 CCCCAGCAGC GGCGGCGGCT CGGAGCGGGC TCCGGGGCTC GGGTGCAGCG
 +106 Oligo-F GCCAGCGGGC GCCTGGCGGC GAGGATTACC CGGGGAAGTG GTTGTCTCCT

+156 GGCTGGAGCC GCGAGACGGG CGCTCAGGGC GCGGGGCCGG CGGCAGCGAA

3/8

FIG. 2B

+206 CGAGAGGACG GACTCTGGCG GCCGGGTCTT TGGCCGCGGG GAGCGCGGGC
 +256 ACCGGGCGAG CAGGCCGCGT CGCGCTCACC ATGGTCAGCT ACTGGGACAC
 +306 CGGGGTCTG CTGTGCGCGC TGCTCAGCTG TCTGCTTCTC ACAGGTGAGG
 +356 CGCGGCTGGG GGCGGGGCC TGAGGGGGC TGCGATGGGG CGGCCGGAGG
 +406 GCAGAGCCTC CGAGGCCAGG GCGGGGTGCA CGCGGGGAGA CGAGGCTGTA
 Transcription arrest site
 +456 GCCCGGAGAA GCTGGCTACG GCGAGAACCT GGGACACTAG TTGCAGCGGG
 +506 CACGCTTGGG GCCGCTGCGC CCTTCTCCG AGGGAGCGCC TCGAG

FIG. 8

flt-1 intron	+408	+432
	AGAGCCTCCGAGGCCAGGGCGGGGT	
	*** * ***** * ***** **	
ADA intron 1	+133	+157
	AGGGGCTCCGTT <u>GCCAGGGTTCTGT</u>	

FIG. 3




FIG. 4





FIG. 5



7/8

FIG. 6A






FIG. 6B



8/8

FIG. 7



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/16581

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; C12N 15/63, 15/85, 15/86; G01N 33/53; A61K 48/00
 US CL : 536/24.1; 435/7.1, 240.2, 320.1; 514/44; 424/93.21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/24.1; 435/7.1, 240.2, 320.1; 514/44; 424/93.21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, EMBASE, BIOSIS, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P ---	MORISHITA et al. A Novel Promoter for Vascular Endothelial Growth Factor Receptor (flt-1) That Confers Endothelial-specific Gene Expression. Journal of Biological Chemistry. 17 November 1995, Vol. 270, No. 46, pages 27948-27953, see entire document.	1-20 ----- 21-41
X,P ---	RONICKE et al. Characterization of the Endothelium-Specific Murine Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter. Circulation Research. August 1996, Vol. 79, No 2, pages 277-285, see entire document.	1-20 ----- 21-41
X,P ---	IKEDA et al. Characterization of the Promoter Region for flt-1 Tyrosine Kinase Gene, A Receptor for Vascular Endothelial Growth Factor. Growth Factors. 1996, Vol. 13, pages 151-162, see entire document.	1-20 ----- 21-41

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
E earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*&*	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 DECEMBER 1996

Date of mailing of the international search report

31 JAN 1997

Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Authorized officer

D. CURTIS HOGUE, JR.

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/16581

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PAJUSOLA et al. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. <i>Oncogene</i> . 1993, Vol. 8, pages 2931-2937, see entire document.	1-41
Y	GALLAND et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. <i>Oncogene</i> . May 1993, Vol. 8, No. 5, pages 1233-1240, see entire document.	1-41

